Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas

dc.contributor.authorAyçiçek Doğan, Berçem
dc.contributor.authorTuna, Mazhar Müslüm
dc.contributor.authorArduç, Ayşe
dc.contributor.authorBaşaran, Mehtap Navdar
dc.contributor.authorKüçükler, Ferit Kerim
dc.contributor.authorDağdelen, İffet
dc.contributor.authorŞensöz Berker, Dilek
dc.contributor.authorGüler, Serdar
dc.date.accessioned2019-05-10T09:38:52Z
dc.date.available2019-05-10T09:38:52Z
dc.date.issued2015
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description.abstractThe aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.
dc.identifier.citationDoğan, B. A., Tuna, M. M., Arduç, A., Başaran, M. N., Küçükler, K., Dağdelen, I, Şensöz B. D., Güler, S. (2015). Increased risk of unfavorable metabolic outcome in patients with clinically nonfunctioning pituitary adenomas. Hormone and Metabolic Research, 47(09), 652-655.
dc.identifier.doi10.1055/s-0035-1547234
dc.identifier.endpage655en_US
dc.identifier.issn0018-5043
dc.identifier.issue9en_US
dc.identifier.scopusqualityQ2
dc.identifier.startpage652en_US
dc.identifier.urihttps://doi.org/10.1055/s-0035-1547234
dc.identifier.urihttps://hdl.handle.net/11491/524
dc.identifier.volume47en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherGeorg Thieme Verlag
dc.relation.ispartofHormone and Metabolic Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAndrogensen_US
dc.subjectAtherosclerotic Risk Markersen_US
dc.subjectClinically Nonfunctioning Pituitary Adenomasen_US
dc.titleIncreased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas
dc.typeArticle

Dosyalar